New Antipsychotic Strategies: Quetiapine and Risperidone vs. Fluphenazine in Treatment Resistant Schizophrenia - Full Text View

Sponsor:	University of Maryland
Information provided by:	University of Maryland
ClinicalTrials.gov Identifier:	NCT00161018

Purpose

The purpose of this study is to:

Evaluate the efficacy and safety of the new antipsychotics, quetiapine (300-500mg/day) and risperidone (3-4mg/day) compared to each other and to fluphenazine (10-15mg/day), a high potency typical antipsychotic in patients who meet the DSM IV criteria for schizophrenia.
To evaluate the efficacy and safety of quetiapine (1200mg/day) in patients who have not responded to conventional and newer antipsychotics.
To evaluate the effectiveness of quetiapine (300-500mg/day), and risperidone (3-5mg/day) compared to each other and fluphenazine (10-15mg/day) in the treatment of hostility and aggression in treatment-resistant schizophrenic patients.
To evaluate the effectiveness of quetiapine (300-500mg/day) and risperidone (3-5mg/day) compared to each other and fluphenazine (10-15mg/day) on rates of discharge, quality of life, and independent living skills.
To assess prolactin levels and to evaluate any relationship with sexual dysfunction and menstrual irregularities.
To evaluate the possible differential impact of treatment conditions on cognitive functioning including measures of attention, motor speed, problem solving, verbal and visual memory, and verbal processing speed.
To measure changes in weight and health consequences associated with weight changes.

Condition	Intervention	Phase
Schizophrenia	Drug: Quetiapine, Risperidone, Fluphenazine	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Dose Comparison, Parallel Assignment

Resource links provided by NLM:

MedlinePlus related topics: Schizophrenia

Drug Information available for: Fluphenazine Risperidone Quetiapine Quetiapine fumarate Fluphenazine hydrochloride Fluphenazine enanthate Fluphenazine depot

U.S. FDA Resources

Further study details as provided by University of Maryland:

Primary Outcome Measures:

To evaluate the efficacy and safety of the new antipsychotics, quetiapine(300-500mg/day) and risperidone(3-5mg/day) compared to each other and to fluphenazine(10-15mg/day), a high potency typical antipsychotic

Estimated Enrollment:	150
Study Start Date:	November 2003
Study Completion Date:	November 2004

Detailed Description:

This is a three arm multi-center randomized double-blind study. After open label treatment with each individual being optimized with routine antipsychotic treatment for 4-6 weeks to prospectively establish lack of response to conventional antipsychotic therapy, approximately 180 patients with schizophrenia who are experiencing clinically significant psychotic symptoms will be recruited (minimum 150 enrolled) in the double-blind period of the study. All participants will sign consent forms before participating in this research study. If participants choose to enroll in the high dose quetiapine arm (period IIIb), they will sign an additional consent form before entering period IIIb.

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Males and Females, between ages 18 and 65 year sof age.
Females of childbearing potential must agree to use medically accepted means of contraception.
A diagnosis of schizophrenia according to the DSM-IV.
Subjects must meet retrospective criteria for treatment-resistance as defined:
1. Persistent positive psychotic symptoms.
2. Current presence of at least a moderately severe illness as rated by the total BPRS.
3. Persistence of illness- No evidence of good functioning in the last five years.
4. Drug-refectory condition defined as at least two periods of treatment in the preceding significant symptom relief.
Subjects must been judged competent to consent by the ESC evaluation and provide voluntary informed consent.
Subjects must be reliable. They must agree to cooperate with all tests and examinations required by the protocol.
Patients msut have a normal ophthalmoscopic exam within 6 months of a full eye exam if any lense abnormality prior to entering study.

Exclusion Criteria:

Females who are either pregnant or lactating.
Serious medical illness including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, neurologic, immunologic, or hematologic disease such that hospitalization for the disease is anticipated within three months or death is anticipated with three years.
History of severe allergies or multiple adverse drug reactions.
DSM-IV substance abuse or dependence within the past month.
Any DSM-IV organic mental disorder.
Judged clinically to be at serious suicidal risk.
Definitive failure to show clinically significant response (improved in CGI score of at least 1 point) to and adequate trial of clozapine (600mg/day for at least 6 weeks)
Uncontrolled seizures within the past 6 months.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00161018

Locations

United States, Maryland
Maryland Psychiatric Research Center
Catonsville, Maryland, United States, 21228

Sponsors and Collaborators

University of Maryland

Investigators

Principal Investigator:

Robert R Conley, MD

MPRC

More Information

No publications provided

Study ID Numbers:	H-20725
Study First Received:	September 8, 2005
Last Updated:	October 8, 2008
ClinicalTrials.gov Identifier:	NCT00161018 History of Changes
Health Authority:	United States: Institutional Review Board; United States: Food and Drug Administration

Additional relevant MeSH terms:

Neurotransmitter Agents
Tranquilizing Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Psychotropic Drugs
Risperidone
Central Nervous System Depressants
Dopamine Antagonists
Antipsychotic Agents
Pharmacologic Actions
Schizophrenia

Serotonin Antagonists
Quetiapine
Serotonin Agents
Mental Disorders
Therapeutic Uses
Fluphenazine depot
Dopamine Agents
Fluphenazine
Central Nervous System Agents
Schizophrenia and Disorders with Psychotic Features

ClinicalTrials.gov processed this record on November 27, 2009